A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : NCE / new chemical entity

[Related PubMed/MEDLINE]
Total Number of Papers: 103
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   NCE  (>> Co-occurring Abbreviation)
Long Form:   new chemical entity
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Analysis of the clinical antibacterial and antituberculosis pipeline. ---
2019 In vivo models and decision trees for formulation development in early drug development: A review of current practices and recommendations for biopharmaceutical development. FIH
2018 An overview of the safety pharmacology society strategic plan. ---
2018 Physicochemical, pharmacokinetic, efficacy and toxicity profiling of a potential nitrofuranyl methyl piperazine derivative IIIM-MCD-211 for oral tuberculosis therapy via in-silico-in-vitro-in-vivo approach. MIC, Mtb, P-gp, PAMPA, RED, RLM, TB, WBC
2017 Characterization and Trypanocidal Activity of a Novel Pyranaphthoquinone. ---
2017 Characterization of 1-Aminobenzotriazole and Ketoconazole as Novel Inhibitors of Monoamine Oxidase (MAO): An In Vitro Investigation. 4-HQ, MAO
2017 Early-Stage Formulation Considerations. NME
2017 The Drug Discovery and Development Industry in India-Two Decades of Proprietary Small-Molecule R&D. ---
2016 New Screening Criteria Setting on Evaluation of Cytochrome P450 Induction Using HepaRG Cells with Multiplex Branched DNA Technologies in Early Drug Discovery. mRNA
10  2016 Pharmacokinetics in Drug Discovery: An Exposure-Centred Approach to Optimising and Predicting Drug Efficacy and Safety. ADME, DMPK, PK
11  2015 Biophysics and Molecular Biology of Cardiac Ion Channels for the Safety Pharmacologist. AP, CIPA, TdP
12  2015 CNS Adverse Effects: From Functional Observation Battery/Irwin Tests to Electrophysiology. CNS, FOB
13  2015 Food Effect in Humans: Predicting the Risk Through In Vitro Dissolution and In Vivo Pharmacokinetic Models. AUC, BCS, FE, IVIVR
14  2015 Haemodynamic Assessment in Safety Pharmacology. ---
15  2015 Sensitivity and Specificity of the In Vitro Guinea Pig Papillary Muscle Action Potential Duration for the Assessment of Drug-Induced Torsades De Pointes Liability in Humans. AP, TdP
16  2015 The Safety Pharmacology of Auditory Function. ---
17  2014 "New drug" designations for new therapeutic entities: new active substance, new chemical entity, new biological entity, new molecular entity. NAS, NBE, NME, NTEs
18  2014 A systematic evaluation of solubility enhancing excipients to enable the generation of permeability data for poorly soluble compounds in Caco-2 model. BCRP, BSA, DMA, HBSS, LY, P-gp, PEG, TEER
19  2014 Effects of nanosuspension formulations on transport, pharmacokinetics, in vivo targeting and efficacy for poorly water-soluble drugs. ---
20  2014 Effects of proarrhythmic drugs on relaxation time and beating pattern in rat engineered heart tissue. EHT, FTPC
21  2014 Nanosuspensions as a versatile carrier based drug delivery system--an overview. API
22  2014 Pharmacokinetics. ADME, PD, PK
23  2014 Pre-clinical pharmacokinetics and acute toxicological evaluation of a monastrol derivative anticancer candidate LaSOM 65 in rats. ---
24  2014 Replicated, replicable and relevant-target engagement and pharmacological experimentation in the 21st century. ---
25  2014 The first approved agent in the Glitazar's Class: Saroglitazar. ---
26  2013 Establishing in vitro to clinical correlations in the evaluation of cardiovascular safety pharmacology. ---
27  2013 Physico chemical characterization of a novel anti-cancer agent and its comparison to Taxol(). ---
28  2013 Risk in vaccine research and development quantified. ---
29  2013 Role of toxicogenomics in the development of safe, efficacious and novel anti-microbial therapies. ---
30  2013 Safety pharmacology investigations in toxicology studies: an industry survey. CIS, NH, SP
31  2013 Safety pharmacology--current and emerging concepts. ICH, SP
32  2012 Assessment of substance abuse liability in rodents: self-administration, drug discrimination, and locomotor sensitization. CNS
33  2012 Comprehensive investigation of the influence of acidic, basic, and organic mobile phase compositions on bioanalytical assay sensitivity in positive ESI mode LC/MS/MS. PK
34  2012 Direct affinity screening chromatography-mass spectrometry assay for identification of antibacterial agents from natural product sources. ---
35  2012 Early phase drug development for treatment of chronic pain--options for clinical trial and program design. ---
36  2012 Methodological innovations expand the safety pharmacology horizon. FIH, JPTM, SPS
37  2012 Non-clinical toxicological considerations for pharmaceutical salt selection. ---
38  2012 The development and registration of topical pharmaceuticals. API
39  2011 A hidden Markov model to assess drug-induced sleep fragmentation in the telemetered rat. ---
40  2011 An overview of colorimetric assay methods used to assess survival or proliferation of mammalian cells. ---
41  2011 Animal models of systemic lupus erythematosus (SLE) and ex vivo assay design for drug discovery. SLE
42  2011 Antitubercular effect of 8-[(4-Chloro phenyl) sulfonyl]-7-Hydroxy-4-Methyl-2H-chromen-2-One in guinea pigs. ---
43  2011 Modern drug discovery technologies: opportunities and challenges in lead discovery. ---
44  2011 Recent advances and novel strategies in pre-clinical formulation development: an overview. BCS
45  2011 Recent patents on oral combination drug delivery and formulations. CNS, CVS
46  2011 The gold industry standard for risk and cost of drug and vaccine development revisited. ---
47  2011 The novel chemical entity YTR107 inhibits recruitment of nucleophosmin to sites of DNA damage, suppressing repair of DNA double-strand breaks and enhancing radiosensitization. NPM
48  2011 Traditional medicine: past, present and future research and development prospects and integration in the National Health System of Cameroon. WHO
49  2011 Use of amino acids as counterions improves the solubility of the BCS II model drug, indomethacin. BCS II, DSC, TGA
50  2010 Antidepressant/anxiolytic and anti-nociceptive effects of novel 2-substituted 1,4-benzodiazepine-2-ones. ---
51  2010 Drug penetration model of vinblastine-treated Caco-2 cultures. P-gp, VB-Caco-2
52  2010 Integration of physicochemical and pharmacokinetic parameters in lead optimization: a physiological pharmacokinetic model based approach. PBPK, PoC
53  2010 Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. SAEs
54  2010 NMR spectroscopy as a tool to close the gap on metabolite characterization under MIST. MIST
55  2010 Non-clinical models: validation, study design and statistical consideration in safety pharmacology. CRO, FIH, JPTM
56  2010 Novel MS solutions inspired by MIST. CAD, ICH
57  2010 Phenocopy--a strategy to qualify chemical compounds during hit-to-lead and/or lead optimization. ---
58  2010 Simultaneous determination of tolbutamide, omeprazole, midazolam and dextromethorphan in human plasma by LC-MS/MS--a high throughput approach to evaluate drug-drug interactions. ISR, ISs
59  2010 The continuing evolution of torsades de pointes liability testing methods: is there an end in sight? ADR, hERG, IRA, TdP
60  2009 Beyond the safety assessment of drug-mediated changes in the QT interval... what's next? TdeP
61  2009 In vitro assessment of P450 induction potential of novel chemopreventive agents SR13668, 9-cis-UAB30, and pentamethychromanol in primary cultures of human hepatocytes. DDI, PMCol
62  2009 Site of metabolism prediction for six biotransformations mediated by cytochromes P450. AUC, CYP450, ROC, SOM
63  2008 Changing need for bioanalysis during drug development. ---
64  2008 Cytochrome P450s in the development of target-based anticancer drugs. ---
65  2008 In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions. DDIs
66  2008 Preformulation considerations for controlled release dosage forms. Part I. Selecting candidates. CR, DS, IR
67  2008 Simultaneous determination of hydrazinocurcumin and phenol red in samples from rat intestinal permeability studies: HPLC method development and validation. HZC, RP, SPIP
68  2008 The IND application. IND
69  2008 The preclinical testing strategy for the development of novel chemical entities for the treatment of asthma. LABA
70  2007 Cytochrome P450 inhibition assays using traditional and fluorescent substrates. ---
71  2007 Cytochrome P450 reaction-phenotyping: an industrial perspective. ---
72  2007 Economic evaluation of a Bayesian model to predict late-phase success of new chemical entities. ---
73  2007 Neuronal nicotinic receptors: a perspective on two decades of drug discovery research. nAChRs
74  2007 Prioritization of clinical drug interaction studies using in vitro cytochrome P450 data: proposed refinement and expansion of the "rank order" approach. ---
75  2006 A novel workflow for the inverse QSPR problem using multiobjective optimization. IQW, QSPR
76  2006 Clinical chemistry and haematology historical data in control Sprague-Dawley rats from pre-clinical toxicity studies. A/G, ALP, ALT, GLP, MCH, MCV, RBC, WBC
77  2006 Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. ---
78  2006 Introduction to early in vitro identification of metabolites of new chemical entities in drug discovery and development. LC/MS
79  2006 Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. CD, DDIs, HTS
80  2006 Safety pharmacology in focus: new methods developed in the light of the ICH S7B guidance document. SPS
81  2006 Standard morphologic evaluation of the heart in the laboratory dog and monkey. BW, HW
82  2006 Utility of mass spectrometry for in-vitro ADME assays. DMPK
83  2005 Accelerated cytotoxicity mechanism screening using drug metabolising enzyme modulators. ACMS
84  2005 Drug-induced QT dispersion: does it predict the risk of torsade de pointes? TdP
85  2005 Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. ---
86  2004 An overview of some pharmacological methods used in safety pharmacology studies. ---
87  2004 Lipophilicity - beyond octanol/water: a short comparison of modern technologies. ADME
88  2004 Mass spectrometry in drug discovery: a current review. ADME, PK
89  2004 The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development. ---
90  2003 The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. ADME, ADMET
91  2002 Clickhaler dry powder inhaler: focussed in vitro proof of principle evaluation of a new chemical entity for asthma. FPF
92  2002 Genotyping and phenotyping the cytochrome p-450 enzymes. CYPs
93  2002 In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: application to the preclinical cardiovascular safety pharmacology of a new chemical entity. ---
94  2001 Evaluation and selection of bio-relevant dissolution media for a poorly water-soluble new chemical entity. SLS
95  2000 Designing and interpreting the results of first-time-to-man studies. ---
96  1997 Safety assessment of pharmaceuticals: examples of inadequate assessments and a mechanistic approach to assuring adequate assessment. ---
97  1997 [Pre-clinical and clinical electrophysiological studies for the prediction of iatrogenic proarrhythmic effect (torsade de pointes)]. dogs
98  1996 [New intravenous anesthetics. Remifentanil, S(+)-ketamine, eltanolone and target controlled infusion]. ET50, TCI
99  1994 The new drug approvals of 1990, 1991, and 1992: trends in drug development. FDA, IND, NDA
100  1993 Psychotherapeutic Medications Development Program (PMDP). PMDP